INTRODUCTION: To better understand the efficacy of liver SBRT we reviewed our prospectively collected institutional SBRT database. METHODS: Between May 2008 and March 2013, 80 patients with 104 liver lesions received SBRT. The Kaplan-Meier method estimated local control (LC), overall survival (OS). Cox proportional hazards regression models identified factors associated with LC and OS. RESULTS: The median follow-up for living patients was 38.6 months. Patients had primary (n=17) or metastatic (n=63) tumors. The median tumor size was 2.7 cm (range, 0.6-14.0). The 1 and 4 year rates of LC were 89.4% and 88%, respectively. Colorectal (CRC) metastasis was associated with lower rates of LC (p=0.013). OS at 1 and 4 years was 78% and 25%, respectively. Patients with CRC metastases had higher rates of OS (p=0.03). The occurrence of severe acute and late toxicity was 3.8% and 6.3%, respectively. CONCLUSIONS: SBRT should be studied in prospective clinical trials compared with other liver-directed treatment modalities.
INTRODUCTION: To better understand the efficacy of liver SBRT we reviewed our prospectively collected institutional SBRT database. METHODS: Between May 2008 and March 2013, 80 patients with 104 liver lesions received SBRT. The Kaplan-Meier method estimated local control (LC), overall survival (OS). Cox proportional hazards regression models identified factors associated with LC and OS. RESULTS: The median follow-up for living patients was 38.6 months. Patients had primary (n=17) or metastatic (n=63) tumors. The median tumor size was 2.7 cm (range, 0.6-14.0). The 1 and 4 year rates of LC were 89.4% and 88%, respectively. Colorectal (CRC) metastasis was associated with lower rates of LC (p=0.013). OS at 1 and 4 years was 78% and 25%, respectively. Patients with CRC metastases had higher rates of OS (p=0.03). The occurrence of severe acute and late toxicity was 3.8% and 6.3%, respectively. CONCLUSIONS: SBRT should be studied in prospective clinical trials compared with other liver-directed treatment modalities.
Entities:
Keywords:
liver metastasis; liver tumor; local control; radiation therapy; radiation-induced liver disease; stereotactic body radiotherapy
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: L A Dawson; C J McGinn; D Normolle; R K Ten Haken; S Walker; W Ensminger; T S Lawrence Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: Brandon M Barney; Kenneth R Olivier; O Kenneth Macdonald; Luis E Fong de Los Santos; Robert C Miller; Michael G Haddock Journal: Am J Clin Oncol Date: 2012-12 Impact factor: 2.339
Authors: Brandon M Barney; Svetomir N Markovic; Nadia N Laack; Robert C Miller; Jann N Sarkaria; O Kenneth Macdonald; Heather J Bauer; Kenneth R Olivier Journal: Int J Radiat Oncol Biol Phys Date: 2013-09-01 Impact factor: 7.038
Authors: Ali Ajdari; Yunhe Xie; Christian Richter; Maximilian Niyazi; Dan G Duda; Theodore S Hong; Thomas Bortfeld Journal: JCO Clin Cancer Inform Date: 2021-03
Authors: Michael P Gustafson; Svetlana Bornschlegl; Sean S Park; Dennis A Gastineau; Lewis R Roberts; Allan B Dietz; Christopher L Hallemeier Journal: Adv Radiat Oncol Date: 2017-08-18
Authors: Sanne Nieuwenhuizen; Madelon Dijkstra; Robbert S Puijk; Bart Geboers; Alette H Ruarus; Evelien A Schouten; Karin Nielsen; Jan J J de Vries; Anna M E Bruynzeel; Hester J Scheffer; M Petrousjka van den Tol; Cornelis J A Haasbeek; Martijn R Meijerink Journal: Curr Oncol Rep Date: 2022-03-17 Impact factor: 5.945